Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders.

MLA

Prisciandaro, James J., et al. “Results from a Randomized, Double-Blind, Placebo-Controlled, Crossover, Multimodal-MRI Pilot Study of Gabapentin for Co-Occurring Bipolar and Cannabis Use Disorders.” Addiction Biology, vol. 27, no. 1, Jan. 2022, p. e13085. EBSCOhost, https://doi.org/10.1111/adb.13085.

APA

Prisciandaro, J. J., Mellick, W., Squeglia, L. M., Hix, S., Arnold, L., & Tolliver, B. K. (2022). Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders. Addiction Biology, 27(1), e13085. https://doi.org/10.1111/adb.13085

Chicago

Prisciandaro, James J, William Mellick, Lindsay M Squeglia, Sara Hix, Lauren Arnold, and Bryan K Tolliver. 2022. “Results from a Randomized, Double-Blind, Placebo-Controlled, Crossover, Multimodal-MRI Pilot Study of Gabapentin for Co-Occurring Bipolar and Cannabis Use Disorders.” Addiction Biology 27 (1): e13085. doi:10.1111/adb.13085.